Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma
Phase 1
Completed
- Conditions
- Stage IV MelanomaStage III Melanoma
- Interventions
- Drug: IMP321 (eftilagimod alpha)
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Immutep Australia Pty. Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02676869
- Locations
- 🇦🇺
Royal Brisbane Womens Hospital, Brisbane, Queensland, Australia
🇦🇺Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺Greenslopes Private Hospital, Brisbane, Queensland, Australia
News
No news found